Statements (29)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
investigational drug |
| gptkbp:CASNumber |
329093-07-4
|
| gptkbp:developedBy |
gptkb:Cyclacel_Pharmaceuticals
|
| gptkbp:discoveredBy |
gptkb:Laurent_Meijer
gptkb:David_Lane |
| gptkbp:hasInChIKey |
QXJYYZQXAFYFJA-UHFFFAOYSA-N
|
| gptkbp:hasMolecularFormula |
C19H26N6O
|
| gptkbp:hasSMILES |
CC(C)N1C=NC2=C1N=CN2C(C3=CC=CC=C3)NCC(O)C
|
| gptkbp:hasUNII |
6Z5B6HVF6O
|
| https://www.w3.org/2000/01/rdf-schema#label |
seliciclib
|
| gptkbp:investigated_for_treatment_of |
gptkb:cancer
gptkb:Cushing's_disease |
| gptkbp:is_in_clinical_trial_phase |
Phase II (as of 2023)
|
| gptkbp:IUPACName |
gptkb:2-(R)-(1-ethyl-2-hydroxyethylamino)-6-benzylamino-9-isopropylpurine
|
| gptkbp:mechanismOfAction |
CDK inhibitor
|
| gptkbp:molecularWeight |
354.45 g/mol
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL297
140995 160355 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:synonym |
gptkb:CYC202
gptkb:roscovitine |
| gptkbp:target |
gptkb:CDK7
gptkb:CDK9 gptkb:CDK2 |
| gptkbp:bfsParent |
gptkb:CYC202
gptkb:CDK2 |
| gptkbp:bfsLayer |
7
|